Status:
COMPLETED
Prevalence of IL28B Polymorphism in Hepatitis C Patients
Lead Sponsor:
Changi General Hospital
Conditions:
Hepatitis C
Eligibility:
All Genders
21-80 years
Brief Summary
Response to peginterferon and ribavirin treatment in hepatitis C (HCV) depends on viral and host factors. Single nucleotide polypmorphisms (SNP) near to IL28B gene (especially at rs12979860 and rs8099...
Detailed Description
The prevalence of different genotypes of IL28B polymorphism in the local population will be studied. DNA will be extracted from the whole blood sample of hepatitis C patients with genotype 1, 2 and 3 ...
Eligibility Criteria
Inclusion
- Patients with positive HCV IgG (EIA or RIBA test) and positive HCV RNA test (RT-PCR)
- HCV genotypes 1, 2 or 3 (determined by Versant™ HCV genotype Assay LiPA 2.0)
- with or without HCV treatment (peginterferon/ ribavirin).
Exclusion
- Patients with acute hepatitis C infection.
Key Trial Info
Start Date :
June 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT03415009
Start Date
June 1 2014
End Date
December 1 2016
Last Update
January 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changi General Hospital
Singapore, Singapore, 529889